What’s happening?

[anonymous]

Thoughts about todays call?

 

[anonymous]

Thoughts about todays call?

lecanumab in

zuranolone in

MS Meh

Biosimilars will be gone shortly.

 

[anonymous]

Son of Aduhell will do better (pretty much impossible for it not to) but will still significantly disappoint.

 

[anonymous]

Son of Aduhell will do better (pretty much impossible for it not to) but will still significantly disappoint.

It will do worse - likely won’t get CMS coverage either. Aduhelm ruined this class of meds.

 

[anonymous]

Son of Aduhell is only marginally effective, difficult to administer and very dangerous. Other than that, everything is cool though.

 

[anonymous]

It will do worse - likely won’t get CMS coverage either. Aduhelm ruined this class of meds.

Not saying it will do well, but it will get CMS coverage. They already stated in the coverage determination that they would cover if fully approved. FDA already stated they would take positive phase 3 as the confirmatory trial for full approval. Data is done and positive, so they just have to file for it.

 

[anonymous]

Son of Aduhell is only marginally effective, difficult to administer and very dangerous. Other than that, everything is cool though.

it’s effective, shouldn’t be on blood thinners, will get CMS coverage, and will be a huge block buster. Zura and Lec!!! Big year for Biogen!!!

 

[anonymous]

Son of Aduhell will do better (pretty much impossible for it not to) but will still significantly disappoint.

!

 

[anonymous]

Sorry for the Alzheimer’s team..if you can move to MS you’ll be safer. MS isn’t on the chopping block.